213 related articles for article (PubMed ID: 29579332)
1. Late therapeutic intervention with a respiratory syncytial virus L-protein polymerase inhibitor, PC786, on respiratory syncytial virus infection in human airway epithelium.
Brookes DW; Coates M; Allen H; Daly L; Constant S; Huang S; Hows M; Davis A; Cass L; Ayrton J; Knowles I; Strong P; Rapeport G; Ito K
Br J Pharmacol; 2018 Jun; 175(12):2520-2534. PubMed ID: 29579332
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor.
Coates M; Brookes D; Kim YI; Allen H; Fordyce EAF; Meals EA; Colley T; Ciana CL; Parra GF; Sherbukhin V; Stockwell JA; Thomas JC; Hunt SF; Anderson-Dring L; Onions ST; Cass L; Murray PJ; Ito K; Strong P; DeVincenzo JP; Rapeport G
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28652242
[TBL] [Abstract][Full Text] [Related]
3. Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium.
Mirabelli C; Jaspers M; Boon M; Jorissen M; Koukni M; Bardiot D; Chaltin P; Marchand A; Neyts J; Jochmans D
J Antimicrob Chemother; 2018 Jul; 73(7):1823-1829. PubMed ID: 29596680
[TBL] [Abstract][Full Text] [Related]
4. Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.
DeVincenzo J; Cass L; Murray A; Woodward K; Meals E; Coates M; Daly L; Wheeler V; Mori J; Brindley C; Davis A; McCurdy M; Ito K; Murray B; Strong P; Rapeport G
J Infect Dis; 2022 Jun; 225(12):2087-2096. PubMed ID: 33216113
[TBL] [Abstract][Full Text] [Related]
5. Molecular Basis for the Selective Inhibition of Respiratory Syncytial Virus RNA Polymerase by 2'-Fluoro-4'-Chloromethyl-Cytidine Triphosphate.
Deval J; Hong J; Wang G; Taylor J; Smith LK; Fung A; Stevens SK; Liu H; Jin Z; Dyatkina N; Prhavc M; Stoycheva AD; Serebryany V; Liu J; Smith DB; Tam Y; Zhang Q; Moore ML; Fearns R; Chanda SM; Blatt LM; Symons JA; Beigelman L
PLoS Pathog; 2015 Jun; 11(6):e1004995. PubMed ID: 26098424
[TBL] [Abstract][Full Text] [Related]
6. Development of an allosteric inhibitor class blocking RNA elongation by the respiratory syncytial virus polymerase complex.
Cox RM; Toots M; Yoon JJ; Sourimant J; Ludeke B; Fearns R; Bourque E; Patti J; Lee E; Vernachio J; Plemper RK
J Biol Chem; 2018 Oct; 293(43):16761-16777. PubMed ID: 30206124
[TBL] [Abstract][Full Text] [Related]
7. Induction and Antagonism of Antiviral Responses in Respiratory Syncytial Virus-Infected Pediatric Airway Epithelium.
Villenave R; Broadbent L; Douglas I; Lyons JD; Coyle PV; Teng MN; Tripp RA; Heaney LG; Shields MD; Power UF
J Virol; 2015 Dec; 89(24):12309-18. PubMed ID: 26423940
[TBL] [Abstract][Full Text] [Related]
8. Comparative Therapeutic Potential of ALX-0171 and Palivizumab against Respiratory Syncytial Virus Clinical Isolate Infection of Well-Differentiated Primary Pediatric Bronchial Epithelial Cell Cultures.
Broadbent L; Parke HG; Ferguson LJ; Millar A; Shields MD; Detalle L; Power UF
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767728
[TBL] [Abstract][Full Text] [Related]
9. New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase.
Fearns R; Deval J
Antiviral Res; 2016 Oct; 134():63-76. PubMed ID: 27575793
[TBL] [Abstract][Full Text] [Related]
10. Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses.
Ohol YM; Wang Z; Kemble G; Duke G
PLoS One; 2015; 10(12):e0144648. PubMed ID: 26659560
[TBL] [Abstract][Full Text] [Related]
11. Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies.
Kinder JT; Moncman CL; Barrett C; Jin H; Kallewaard N; Dutch RE
J Virol; 2020 Sep; 94(20):. PubMed ID: 32759319
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection.
Wang G; Deval J; Hong J; Dyatkina N; Prhavc M; Taylor J; Fung A; Jin Z; Stevens SK; Serebryany V; Liu J; Zhang Q; Tam Y; Chanda SM; Smith DB; Symons JA; Blatt LM; Beigelman L
J Med Chem; 2015 Feb; 58(4):1862-78. PubMed ID: 25667954
[TBL] [Abstract][Full Text] [Related]
13. Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans.
Patel K; Kirkpatrick CM; Nieforth KA; Chanda S; Zhang Q; McClure M; Fry J; Symons JA; Blatt LM; Beigelman L; DeVincenzo JP; Huntjens DR; Smith PF
J Antimicrob Chemother; 2019 Feb; 74(2):442-452. PubMed ID: 30376079
[TBL] [Abstract][Full Text] [Related]
14. Water extract of licorice had anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines.
Feng Yeh C; Wang KC; Chiang LC; Shieh DE; Yen MH; San Chang J
J Ethnopharmacol; 2013 Jul; 148(2):466-73. PubMed ID: 23643542
[TBL] [Abstract][Full Text] [Related]
15. 4'-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication.
Sourimant J; Lieber CM; Aggarwal M; Cox RM; Wolf JD; Yoon JJ; Toots M; Ye C; Sticher Z; Kolykhalov AA; Martinez-Sobrido L; Bluemling GR; Natchus MG; Painter GR; Plemper RK
Science; 2022 Jan; 375(6577):161-167. PubMed ID: 34855509
[TBL] [Abstract][Full Text] [Related]
16. JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase.
Bonneux B; Shareef A; Tcherniuk S; Anson B; de Bruyn S; Verheyen N; Thys K; Conceição-Neto N; Van Ginderen M; Kwanten L; Ysebaert N; Vranckx L; Peeters E; Lanckacker E; Gallup JM; Sitthicharoenchai P; Alnajjar S; Ackermann MR; Adhikary S; Bhaumik A; Patrick A; Fung A; Sutto-Ortiz P; Decroly E; Mason SW; Lançois D; Deval J; Jin Z; Eléouët JF; Fearns R; Koul A; Roymans D; Rigaux P; Herschke F
Antiviral Res; 2024 Jul; 227():105907. PubMed ID: 38772503
[TBL] [Abstract][Full Text] [Related]
17. The effect of respiratory synctial virus on chemokine release by differentiated airway epithelium.
Mellow TE; Murphy PC; Carson JL; Noah TL; Zhang L; Pickles RJ
Exp Lung Res; 2004; 30(1):43-57. PubMed ID: 14967603
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone inhibits respiratory syncytial virus-driven mucus production while increasing viral replication without altering antiviral interferon signaling.
McAllister CS; Ansaldi D; Growcott EJ; Zhong Y; Quackenbush D; Wolff KC; Chen Z; Tanaseichuk O; Lelais G; Barnes SW; Federe GC; Luna F; Walker JR; Zhou Y; Kuhen KL
Virology; 2020 Jan; 540():195-206. PubMed ID: 31929001
[TBL] [Abstract][Full Text] [Related]
19. GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process.
Perron M; Stray K; Kinkade A; Theodore D; Lee G; Eisenberg E; Sangi M; Gilbert BE; Jordan R; Piedra PA; Toms GL; Mackman R; Cihlar T
Antimicrob Agents Chemother; 2015 Dec; 60(3):1264-73. PubMed ID: 26666922
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Placebo-Controlled, Respiratory Syncytial Virus Human Challenge Study of the Antiviral Efficacy, Safety, and Pharmacokinetics of RV521, an Inhibitor of the RSV-F Protein.
DeVincenzo J; Tait D; Efthimiou J; Mori J; Kim YI; Thomas E; Wilson L; Harland R; Mathews N; Cockerill S; Powell K; Littler E
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
